{'fraction_non_alphanumeric': 0.017195767195767195, 'fraction_numerical': 0.0, 'mean_word_length': 4.9140625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Drs. Nadas and Levy Reply

We share Dr. White's concern about the premature use of new drugs in humans without previous animal experiments and controlled double-blind trials in humans. Our general attitude in regard to these principles might be documented by an editorial about the use of prostaglandin inhibition in the treatment of patent ductus arteriosus in respiratory distress syndrome; a national coordinated double-blind study had been proposed as a sequel to the editorial. In the area of dopamine, a drug we are using extensively to treat low urine output in patients in the cardiac intensive care unit, an abstract summarizing our work, according to a strict protocol, was presented at the February meeting of the American College of Cardiology.